GleamWall
中文EN

GNPX Genprex, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1595248 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-233.7%
ROA-160.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets21.7%
Debt / equity0.00x
Current ratio4.26x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-15.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$0
R&D expense$9.43M$10.54M
SG&A expense$6.09M$10.63M
Operating income-$15.52M-$21.17M
Income tax$0$2,650
Net income-$16.23M-$21.11M
EBITDA-$15.52M-$21.17M
EPS (basic)-17.40-266.89
EPS (diluted)——
Balance sheet
Cash & equivalents$7.83M$1.60M
Current assets$8.36M$2.08M
PP&E, net$0$0
Intangibles—$0
Total assets$10.16M$4.12M
Current liabilities$2.17M$2.50M
Total liabilities$2.20M$2.50M
Shareholders' equity$7.96M$1.62M
Shares outstanding149,811217,234
Cash flow statement
Operating cash flow-$15.31M-$17.92M
Investing cash flow$0$774,644
Financing cash flow$21.54M$12.01M
Depreciation & amortization$0$6,693
Stock-based compensation$300,000$3.30M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.